A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Yangilik qisqacha mazmuni
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Ishonchli nashriyotlarning so‘nggi xabarlarini qisqa izohlar bilan kuzating. Tafsilotlar uchun asl manba havolasini oching.